Abstract
The combination of BRAF-targeted agents with immune checkpoint inhibitors represents a recent advance in the treatment of melanoma, even though each of these therapeutic approaches alone has specific limitations. Increasing evidence suggests indeed the existence of a synergistic interaction between these therapeutic modalities.
Keywords: :
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.